BACKGROUND: Data are limited on human immunodeficiency virus (HIV)-associated influenza burden in sub-Saharan Africa and the impact of highly active antiretroviral therapy (HAART). We compared influenza-related mortality in adults with AIDS in South Africa and the United States in the pre-HAART era and evaluated mortality trends after HAART introduction in the United States. METHODS: Monthly all-cause and pneumonia and influenza (P&I) mortality rates were compiled for adults with AIDS aged 25-54 years in South Africa (1998-2005) and the United States (pre-HAART era, 1987-1994; HAART era, 1997-2005). We estimated influenza-related deaths as excess mortality above a model baseline during influenza epidemic periods. Influenza-related mortality rates in adults with AIDS were compared with rates for age peers in the general population and adults ≥65 years old. RESULTS: In the United States before HAART, influenza-related mortality rates in adults with AIDS were 150 (95% confidence interval [CI], 49-460) and 208 (95% CI, 74-583) times greater than in the general population for all-cause and P&I deaths, respectively, and 2.5 (95% CI, 0.9-7.2) and 4.1 (95% CI, 1.4-13) times higher than in elderly adults. After HAART introduction , influenza-related mortality in adults with AIDS dropped 3-6-fold but remained elevated compared with the general population (all-cause relative risk [RR], 44 [95% CI, 16-121]); P&I RR, 73 [95% CI, 47-113]). Influenza-related mortality in South African adults with AIDS in recent years was similar to that in the United States in the pre-HAART era. CONCLUSIONS: Adults with AIDS experience substantially elevated influenza-associated mortality, which declines with widespread HAART introduction but does not disappear. These data support increased access to HAART and influenza vaccination for HIV-infected adults.
BACKGROUND: Data are limited on human immunodeficiency virus (HIV)-associated influenza burden in sub-Saharan Africa and the impact of highly active antiretroviral therapy (HAART). We compared influenza-related mortality in adults with AIDS in South Africa and the United States in the pre-HAART era and evaluated mortality trends after HAART introduction in the United States. METHODS: Monthly all-cause and pneumonia and influenza (P&I) mortality rates were compiled for adults with AIDS aged 25-54 years in South Africa (1998-2005) and the United States (pre-HAART era, 1987-1994; HAART era, 1997-2005). We estimated influenza-related deaths as excess mortality above a model baseline during influenza epidemic periods. Influenza-related mortality rates in adults with AIDS were compared with rates for age peers in the general population and adults ≥65 years old. RESULTS: In the United States before HAART, influenza-related mortality rates in adults with AIDS were 150 (95% confidence interval [CI], 49-460) and 208 (95% CI, 74-583) times greater than in the general population for all-cause and P&I deaths, respectively, and 2.5 (95% CI, 0.9-7.2) and 4.1 (95% CI, 1.4-13) times higher than in elderly adults. After HAART introduction , influenza-related mortality in adults with AIDS dropped 3-6-fold but remained elevated compared with the general population (all-cause relative risk [RR], 44 [95% CI, 16-121]); P&I RR, 73 [95% CI, 47-113]). Influenza-related mortality in South African adults with AIDS in recent years was similar to that in the United States in the pre-HAART era. CONCLUSIONS: Adults with AIDS experience substantially elevated influenza-associated mortality, which declines with widespread HAART introduction but does not disappear. These data support increased access to HAART and influenza vaccination for HIV-infected adults.
Authors: Anthony E Fiore; Timothy M Uyeki; Karen Broder; Lyn Finelli; Gary L Euler; James A Singleton; John K Iskander; Pascale M Wortley; David K Shay; Joseph S Bresee; Nancy J Cox Journal: MMWR Recomm Rep Date: 2010-08-06
Authors: A D Fine; C B Bridges; A M De Guzman; L Glover; B Zeller; S J Wong; I Baker; H Regnery; K Fukuda Journal: Clin Infect Dis Date: 2001-05-16 Impact factor: 9.079
Authors: Shabir A Madhi; Nini Ramasamy; Terry G Bessellar; Haroon Saloojee; Keith P Klugman Journal: Pediatr Infect Dis J Date: 2002-04 Impact factor: 2.129
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Matthew J Cummings; Barnabas Bakamutumaho; Wan Yang; Joseph F Wamala; John Kayiwa; Nicholas Owor; Barbara Namagambo; Timothy Byaruhanga; Allison Wolf; Julius J Lutwama; Jeffrey Shaman; Max R O'Donnell Journal: Am J Trop Med Hyg Date: 2018-01-01 Impact factor: 2.345
Authors: Tochukwu Raphael Abadom; Adrian D Smith; Stefano Tempia; Shabir A Madhi; Cheryl Cohen; Adam L Cohen Journal: Vaccine Date: 2016-10-06 Impact factor: 3.641
Authors: Matthew J Cummings; Barnabas Bakamutumaho; John Kayiwa; Timothy Byaruhanga; Nicholas Owor; Barbara Namagambo; Allison Wolf; Joseph F Wamala; Stephen S Morse; Julius J Lutwama; Max R O'Donnell Journal: Ann Am Thorac Soc Date: 2016-12